Metabolism of prazosin in rat, dog, and human liver microsomes and cryopreserved rat and human hepatocytes and characterization of metabolites by liquid chromatography/tandem mass spectrometry

Drug Metabolism and Disposition

Volumn 35, Issue 6, 2007, Pages 908-916

  Erve, John C L ^a   Vashishtha, Sarvesh C ^a   DeMaio, William ^a   Talaat, Rasmy E ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 6,7 DIMETHOXY 2 QUINAZOLINE) 4 (2 PYRAZIDINE)PIPERAZINE; 1 (4 AMINO 6,7 DIMETHOXY QUINAZOLIN 2 YL) 4 (FURAN 2 CARBONYL) 2,3,4,5 TETRAHYDRO PYRAZIN 1 IUM; 2 [4 (2 FURANOYL 3,4 DIHYDRO 2H PYRAZIN 1 YL] 4 AMINO 6,7 DIMETHOXYQUINAZOLINE; 4 (4 AMINO 6,7 DIMETHOXY QUINAZOLIN 2 YL) 1 (FURAN 2 CARBONYL) 2,3,4,5 TETRAHYDROPYRAZIN 1 IUM; 5 [4 (4 AMINO 6,7 DIMETHOXY QUINAZOLIN 2 YL)PIPERAZIN 1 YL] 4,5 DIOXO PENTAN 1 OL; 5 [4 (4 AMINO 6,7 DIMETHOXY QUINAZOLIN 2 YL)PIPERAZIN 1 YL] 4,5 DIOXO PENTANOIC ACID; 6 DESMETHYLPRAZOSIN; 7 DESMETHYLPRAZOSIN; DRUG METABOLITE; ENAMINE; FURAN; GLUTATHIONE; HYDROXYPRAZOSIN; N DESFURANOYLPRAZOSIN; PRAZOSIN; PRAZOSIN N GLUCURONIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GALACTOSE;

ANIMAL CELL; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; CRYOPRESERVATION; DEMETHYLATION; DOG; DRUG METABOLISM; GLUCURONIDATION; HUMAN; HUMAN CELL; HYDROLYSIS; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOTRANSFORMATION; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYOPRESERVATION; DOGS; FEMALE; GLUTATHIONE; HEPATOCYTES; HUMANS; MALE; MICROSOMES, LIVER; NADP; PRAZOSIN; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY; URIDINE DIPHOSPHATE GLUCURONIC ACID; VASODILATOR AGENTS;

CANIS FAMILIARIS; RATTUS;

EID: 34249088106     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013219     Document Type: Article

References (33)

1. Althuis TH and Hess HJ (1977) Synthesis and identification of the major metabolites of prazosin formed in dog and rat. J Med Chem 20:146-149.
2. Bateman DN, Hobbs DC, Twomey TM, Stevens EA, and Rawlins MD (1979) Prazosin, pharmacokinetics and concentration effects. Eur J Pharmacol 16:177-181.
3. Berry MN and Friend DS (1969) High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J Cell Biol 43:506-520.
4. Caldwell GW and Yan Z (2006) Screening for reactive intermediates and toxicity assessment in drug discovery. Curr Opin Drug Disc Dev 9:47-60.
5. Constantine JW (1974) Analysis of the hypotensive action of prazosin, in Prazosin - Evaluation of a New Antihypertensive Agent (Cotton D ed) pp 16-36, Excerpta Medica, Geneva.
6. Daly CM, Doyle ME, Radkind M, Raskind E, and Daniels C (2005) Clinical case series: the use of Prazosin for combat-related recurrent nightmares among operation Iraqi Freedom combat veterans. Mil Med 170:513-515.
7. Dick RA, Kwak MK, Sutter TR, and Kensler TW (2001) Antioxidative function and substrate specificity of NAD(P)H-dependent alkenal/one oxidoreductase. A new role for leukotriene B4 12-hydroxydehydrogenase/15-oxoprostaglandin 13-reductase. J Biol Chem 276:40803-40810.
8. Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, and Wrighton SA (2000) Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods 44:313-324.
9. Evans DC and Baillie TA (2005) Minimizing the potential for metabolic activation as an integral part of drug design. Curr Opin Drug Disc Dev 8:44-50.
10. Hoffman BB and Lefkowitz RJ (1990) Adrenergic receptor antagonists, in The Pharmacological Basis of Therapeutics (Gilman A ed) 8th ed, pp 221-243, Pergamon Press, Elmsford, NY.
11. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, et al. (2005) A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 3:161-225.
12. Kalgutkar AS and Nguyen HT (2005) Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event. Drug Metab Dispos 9:943-952.
13. Kaye B, Cussans NJ, Faulkner JK, Stopher DA, and Reid JL (1986) The metabolism and kinetics of doxazosin in man, mouse, rat and dog. Br J Clin Pharmacol 21 (Suppl 1):19S-25S.
14. Kobayashi T, Ando H, Sugihara J, and Harigaya S (1987a) Metabolism of ethyl 2-(4-chlorophenyl)-5-(2-furyl)-oxazole-4-acetate, a new hypolipidemic agent, in the rat, rabbit and dog. Glucuronidation of carboxyl group and cleavage of furan ring. Pharmacol Exp Ther 15:262-266.
15. Kobayashi T, Sugihara J, and Harigaya S (1987b) Mechanism of metabolic cleavage of a furan ring. Drug Metab Dispos 15:877-881.
16. Le Fur JM and Labaune JP (1985) Metabolic pathway by cleavage of a furan ring. Xenobiotica 15:567-577.
17. Lindstrom TD and Whitaker GW (1984) Saturation of an alpha, beta-unsaturated ketone: a novel xenobiotic biotransformation in mammals. Xenobiotica 14:503-508.
18. McClanahan RH, Thomassen D, Slattery JT, and Nelson SD (1989) Metabolic activation of (R)-(+)-pulegone to a reactive enonal that covalently binds to mouse liver proteins. Chem Res Toxicol 2:349-355.
19. Nassar AE, Talaat RE, and Kamel AM (2006) The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet? Curr Opin Drug Disc Dev 9:61-74.
20. Piotrovskii VK, Veiko NN, Ryabokon OS, Postolnikov SF, and Metelitsa VI (1984) Identification of a prazosin metabolite and some preliminary data on its kinetics in hypertensive patients. Eur J Clin Pharmacol 27:275-280.
21. Prakash C and Soliman V (1997) Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS. Drug Metab Dispos 25:1288-1297.
22. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, Dobie DJ, Hoff D, Rein RJ, Straits-Tröster K, et al. (2003) Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 160:371-373.
23. Rose J and Castagnoli N (1983) The metabolism of tertiary amines. Med Res Rev 3:73-88.
24. Rubin P, Yee YG, Anderson M, and Blaschke T (1979) Prazosin first-pass metabolism and hepatic extraction in the dog. J Cardiovasc Pharmacol 1:641-647.
25. Sayre LM, Engelhart DA, Nadkarni DV, Babu MKM, Flammang AM, and McCoy GD (1997) The role of imimium-enamine species in the toxication and detoxication of cyclic tertiary amines, in Pharmacokinetics, Metabolism and Pharmaceutics of Drugs of Abuse (RS Rapaka ed) pp 106-127, National Institute on Drug Abuse, Rockville, MD.
26. Sohlenius-Sternbeck AK and Schmidt S (2005) Impaired glutathione- conjugating capacity by cryopreserved human and rat hepatocytes. Xenobiotica 35:727-736.
27. Stanaszek WF, Kellerman D, Brogden RN, and Romankiewicz JA (1983) Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs 25:339-384.
28. Taskinen J, Wikberg T, Ottoila P, Kanner L, Lotta T, Pippuri A, and Backstrom R (1991) Identification of major metabolites of the catechol-O-methyltransferase-inhibitor nitecapone in human urine. Drug Metab Dispos 19:178-183.
29. 1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder. J Clin Psychopharmacol 22:82-85.
30. Taylor LA, Twomey TM, and Schuch von Wintenau M (1977) The metabolic fate of prazosin. Xenobiotica 7:357-364.
31. Uetrecht J (2001) Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discov Dev 4:55-59.
32. Uetrecht J (2003) Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov Today 15:832-837.
33. Venkatakrishnan K, Von Moltke LL, and Greenblatt DJ (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179.